Home > Insider Trading > Filing (0001596783-19-000025)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1596783	Catalent Inc.	CTLT	Pharmaceutical Preparations (2834)	208737688

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1612357	Aristippos Gennadios	C/O Catalent, Inc. 14 Schoolhouse Road Somerset NJ 08873	President, Softgel Tech.	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2019-03-21	13,528	$10.71	44,862	No	4	M	Direct
Common Stock	Disposition	2019-03-21	5,794	$42.17	39,068	No	4	F	Direct
Common Stock	Disposition	2019-03-21	950	$42.16	38,118	No	4	F	Direct
Common Stock	Disposition	2019-03-21	3,326	$42.17	34,792	No	4	S	Direct
Common Stock	Disposition	2019-03-21	66	$42.91	34,726	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	F	Direct
No	4	F	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Options to purchase Common Stock	Disposition	2019-03-21	13,528	$0.00	13,528	$10.71

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0	2016-09-09	2019-10-23	No	4	M	Direct

Footnotes

This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in order to implement a plan of financial diversification.
Includes restricted stock units.
Volume-weighted average price. These shares were sold in multiple transactions at prices ranging from $41.84 to $42.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
On October 23, 2009, the reporting person was granted options to purchase 23,240 shares of common stock of the Issuer, which partially vested and became exercisable based on satisfaction of certain performance-based vesting criteria on September 9, 2016. (S1116, S1159)